- Home
- CRSP vs WFG Comparison
CRSP vs WFG Comparison
Compare CRSP & WFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- WFG
- Stock Information
- Founded
- CRSP 2013
- WFG 1955
- Country
- CRSP Switzerland
- WFG Canada
- Employees
- CRSP N/A
- WFG N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- WFG
- Sector
- CRSP Health Care
- WFG
- Exchange
- CRSP Nasdaq
- WFG Nasdaq
- Market Cap
- CRSP 5.6B
- WFG 6.0B
- IPO Year
- CRSP 2016
- WFG N/A
- Fundamental
- Price
- CRSP $71.48
- WFG $68.88
- Analyst Decision
- CRSP Buy
- WFG Strong Buy
- Analyst Count
- CRSP 18
- WFG 3
- Target Price
- CRSP $72.59
- WFG $103.67
- AVG Volume (30 Days)
- CRSP 2.6M
- WFG 220.3K
- Earning Date
- CRSP 11-04-2025
- WFG 10-22-2025
- Dividend Yield
- CRSP N/A
- WFG 1.86%
- EPS Growth
- CRSP N/A
- WFG N/A
- EPS
- CRSP N/A
- WFG N/A
- Revenue
- CRSP $38,050,000.00
- WFG $5,832,000,000.00
- Revenue This Year
- CRSP N/A
- WFG N/A
- Revenue Next Year
- CRSP $388.50
- WFG $8.44
- P/E Ratio
- CRSP N/A
- WFG N/A
- Revenue Growth
- CRSP N/A
- WFG N/A
- 52 Week Low
- CRSP $30.04
- WFG $66.36
- 52 Week High
- CRSP $73.95
- WFG $102.40
- Technical
- Relative Strength Index (RSI)
- CRSP 66.62
- WFG 43.32
- Support Level
- CRSP $67.41
- WFG $67.45
- Resistance Level
- CRSP $73.95
- WFG $68.21
- Average True Range (ATR)
- CRSP 3.46
- WFG 1.58
- MACD
- CRSP 0.87
- WFG 0.00
- Stochastic Oscillator
- CRSP 76.46
- WFG 32.36
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board producers in the world.